Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01627314 · ClinicalTrials.gov registry record · Phase 2
The PUMA Trial is a Trial of a Single ProHema Modulated-Cord Blood (CB) Unit as Part of a Double CB Transplant in Patients With Hematologic Malignancies.
A Phase 2 study, sponsored by Fate Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 62
- Enrollment target
NCT01627314 is a Phase 2 study that was terminated before completion, run by Fate Therapeutics. The registered enrollment target is 62 participants.
The verdict
NCT01627314, a Phase 2 study, was terminated before completion, sponsored by Fate Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 62 participants
- Enrollment target
Study Summary
This study is an open-label randomized, prospectively and historically controlled trial of the safety and efficacy of a single ProHema-CB unit used as part of a double CB transplant following myeloablative or reduced intensity conditioning for subjects age 15-65 years with hematologic malignancies. A maximum of 60 eligible subjects will be enrolled and treated in the trial at approximately 10 centers within the U.S.
Interventions
- BIOLOGICAL ProHema-CB
- BIOLOGICAL Untreated CB
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2012-07 |
| Est. Completion | 2017-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01627314
The ClinicalTrials.gov registry entry for NCT01627314 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fate Therapeutics, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ProHema-CB is the first listed.
NCT01627314 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01627314 about?
NCT01627314 is a clinical study titled "The PUMA Trial is a Trial of a Single ProHema Modulated-Cord Blood (CB) Unit as Part of a Double CB Transplant in Patients With Hematologic Malignancies.". This study is an open-label randomized, prospectively and historically controlled trial of the safety and efficacy of a single ProHema-CB unit used as part of a double CB transplant following myeloablative or reduced intensity conditioning for subjects age 15-65 years with hematologic malignancies. ...
What is the current status of trial NCT01627314?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 62 participants. The study started on 2012-07. Estimated completion is 2017-05.
What interventions are being tested in trial NCT01627314?
The interventions under investigation include: ProHema-CB (BIOLOGICAL), Untreated CB (BIOLOGICAL).
Who is sponsoring clinical trial NCT01627314?
This trial is sponsored by Fate Therapeutics, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.